The global drug-induced immune hemolytic anemia market, valued at approximately USD 7.8 billion in 2023, is poised for substantial growth and is projected to reach USD 13.4 billion by 2033. This ...

Arup associate East Asia security and risk Geoffrey Moore, speaking at the Super Terminal Expo, stated (05-Nov-2024) many airports face the issue of having "very limited choice when it comes to ...

Silicon Laboratories had a negative return on equity of 9.13% and a negative net margin of 36.53%. The business had revenue of $166.00 million for the quarter, compared to analysts’ expectations ...

Revenue: US$166.4m (down 18% from 3Q 2023). Net loss: US$28.5m (down by 376% from US$10.3m profit in 3Q 2023). US$0.88 loss per share (down from US$0.33 profit in 3Q 2023). Revenue was in line ...

Silicon Laboratories (SLAB) has disclosed a new risk, in the Debt & Financing category. Silicon Laboratories faces significant financial risk due to potential borrowings under its credit agreement ...

We will continue to drive efficiency, strengthen our core businesses, and positively impact patient lives through science and innovation,” said G V Prasad, Co-Chairman & MD, Dr Reddy's Laboratories.

(RTTNews) - Below are the earnings highlights for Silicon Laboratories Inc. (SLAB): Earnings: -$28.50 million in Q3 vs. $10.35 million in the same period last year. EPS: -$0.88 in Q3 vs.

Days of Inventory on Hand: Improved to 165 days from 217 days at June quarter-end. Silicon Laboratories Inc (NASDAQ:SLAB) delivered solid third-quarter results with revenue and earnings exceeding ...

Dr Reddys Laboratories Q2 Results Live : Dr Reddys Laboratories announced its Q2 results on November 5, 2024, revealing a mixed performance. The company's topline saw a significant increase of 16. ...

Dr Reddy’s Lab (DRRD) delivered in-line 2QFY25 performance. DRRD exhibited robust YoY growth in North America (NA), Russia, and ROW markets and a healthy scale-up in the pharmaceutical services ...

Purpose: The basic concepts of pharmacogenetics, pharmacogenetic study approaches, factors to consider when applying pharmacogenetic discoveries to patient care, and potential roles for ...

Ikonisys (Euronext Growth Paris: ALIKO), a company specializing in the early and accurate detection of cancers through a unique, fully automated solution for medical analysis laboratories ...